SimonMed Imaging has entered into a partnership with Lunit to deploy AI tools across its breast cancer screening services, marking a broad implementation of Lunit INSIGHT DBT into SimonMed’s nationwide imaging network.

The Scottsdale, Arizona-based imaging provider will incorporate Lunit’s AI technology alongside Volpara Analytics to power its Personalized Breast Cancer Detection (PBCD) program. The tools are aimed at increasing accuracy and consistency in mammogram interpretation, particularly through improved sensitivity and specificity.

SimonMed operates more than 170 centers across 11 states and employs over 200 subspecialty-trained radiologists. The company said the integration is intended to complement its radiologists and deliver faster, more individualized diagnostic results.
“We’ve evaluated a range of AI technologies, and Lunit’s performance, speed, and clinical validation stood above the rest,” said Dr. Sean Raj, chief innovation officer at SimonMed Imaging. “This partnership enables us to offer the most precise and personalized mammogram experience to date.”

Lunit INSIGHT DBT, which is FDA-cleared, is trained on millions of mammography images and is designed to assist in identifying subtle abnormalities. The AI software is already in use at thousands of healthcare institutions globally, according to the Seoul-based company.

Volpara Analytics, developed by New Zealand-based Volpara Health (a Lunit company), will be used in tandem to optimize imaging quality and assess breast density.

The collaboration comes amid growing adoption of AI in diagnostic imaging, particularly in mammography, where clinical guidelines increasingly call for tailored screening approaches based on patient-specific risk factors.

Artificial Intelligence Homepage